Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Cardiovascular Diseases 3Metabolic Syndrome 2Breast Neoplasms 2Stomach Neoplasms 1Sarcoidosis 1Obesity 1Non-alcoholic Fatty Liver Disease 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Lung Diseases, Interstitial 1Liver Cirrhosis 1Hodgkin Disease 1Colorectal Neoplasms 1Cardiotoxicity 1

Interventions

Rituximab 187Cyclophosphamide 174Etoposide 94Peripheral Blood Stem Cell Transplantation 90Vincristine 89Prednisone 80Doxorubicin 79Filgrastim 75fludarabine phosphate 60Radiotherapy 56Mycophenolic Acid 41Melphalan 41Cytarabine 41Busulfan 40Cyclosporine 39Methotrexate 37Whole-Body Irradiation 36Tacrolimus 35Carmustine 34Ifosfamide 28Lenalidomide 27Granulocyte Colony-Stimulating Factor 27Antilymphocyte Serum 27Gemcitabine 25Carboplatin 25Methylprednisolone 24ibritumomab tiuxetan 23Bortezomib 22Dexamethasone 21ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large B-Cell, Diffuse × Blood Pressure × Clear all
NCT05108805 2025-03-27

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Vanderbilt-Ingram Cancer Center

Phase 4 Completed
25 enrolled 17 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡